Opportunistic Infections & Other Complications: Eosinophilic Folliculitis
Seattle Treatment Education Project (STEP) Perspective, Vol. 5, No. 2 - July 1993 * 127 Broadway E. Ste 200 Seattle, WA 98102 Laury McKean, RN
This type of skin rash, which can cause severe itching, is often difficult to treat. Thirty individuals with eosinophilic folliculitis and a mean CD4 count of 67.6 were enrolled in a trial of itraconazole. The participants received doses ranging from 100 mg to 400 mg a day. Therapy was discontinued at the determination of treatment success, treatment failure, or an adverse event. At the various doses, a complete response was obtained in 18 individuals (58%), a partial response in three (10%), and four individuals (13%) failed the therapy. Itraconazole was discontinued in five participants because of skin eruptions in four, and elevated liver enzymes in one individual. After eight weeks of follow up in 10 participants, two remained clear off of treatment, six remained clear on treatment, and two were partially clear on treatment. The investigators concluded that itraconazole showed impressive benefit in the treatment of eosinophilic folliculitis (PO-B20-1887).
9307
STEP5216
Always watch for outdated information. This article first appeard in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.
This information is designed to support, not replace, the relationship that exists between you and your doctor.